Mounting evidence has demonstrated that fatty acid synthase (FAS) is critical in the metabolic reprogramming in EC and is a target for the development of anti-obesity and anti-cancer drugs (8–10). This evidence concerns the gene FAS and obesity due to melanocortin 4 receptor deficiency.